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Summary: Children are therapeutic orphans and an underprivileged group in innovations 
derived from drug therapy. As the innovation process of pharmaceuticals is a long, risky and 
very costly business, economists typically emphasise lack of profit incentives and small 
market size as the most important obstacles to child-related innovative activity. Moreover, as 
new drugs need to be tested in medical trials, there are ethical concerns leading to a climate of 
reluctance towards medical trials on persons who are not able to give their “informed 
consent”. Particularly in Germany, due to various reasons, a rather restrictive legislation is to 
be assumed, characterized by the idea of putting the protection of the individual human being 
before a more utilitarian view. Thus, economic incentives, legal restrictions and ethical 
concerns seem to be responsible for the lack of innovative activity targeted at drugs for 
children, though social cost-benefit considerations (i.e. welfare analysis) would most probably 
predict a high gain from the introduction of critical innovations. Grounded on a highly 
interdisciplinary view based on medical, pharmaceutical, psychopharmaceutical, 
psychotherapeutic and economic research as well as on ethical restrictions, this survey aims at 
analysing channels of influence that might be helpful both in the analysis of the innovation 
process of drugs for children, and in improving the uncertain situation of pediatric therapy. 
  
Authors: 
Prof. Dr. H. Entorf     Prof. Dr. J. M. Fegert   
       Dr. M. Kölch   
 
Department of Economics    Dept. of Child and Adolescent 
Darmstadt University of Technology  Psychiatry and Psychotherapy 
Marktplatz 15      University Hospital of Ulm  
D-64283 Darmstadt     Steinhövelstr. 5 
Germany      D-89075 Ulm – Germany 
 3
1. Introduction  
Children are therapeutic orphans and an underprivileged group in innovations derived from 
drug-therapy. Although the last few years have seen an expansion of child-related research on 
psychotropic medications subsequent to recent legislative incentives to industry (Riddle et al. 
2001, Vitiello et al. 2004), research and development (R&D) has not brought about a 
sufficient availability of newly registered drugs. This market failure has to do with enormous 
R&D costs and potential sunk costs. The innovation process of pharmaceuticals is a long, 
risky and very costly business (see Grabowski, 2003a, for a recent survey). As the size of the 
market determines the amount of sales, economists typically emphasise profit (i.e. sales minus 
costs) incentives and the size of the market as major driving forces of innovative activity. 
Thus, as children have a much lower probability of being a customer of pharmaceutical 
products, market incentives to produce drugs for children and juveniles are rather small.  
In such markets, patent protection and market exclusivity seem to be promising avenues for 
spurring the innovation process. Indeed, the U.S. 1983 Orphan Drug Act (ODA) provides an 
interesting and successful experience worth being considered and adapted as a solution to 
obstacles to the European and German innovation process. ODA covers drugs which treat 
diseases affecting only a small number of people (less than 200,000 in the US, which is 
equivalent to about 7.5 patients / 10,000 inhabitants). The Act is based on economic 
incentives (tax credits, seven-year grant of market exclusivity and federal funding).The 
European Union followed the US example by launching the European Agency for the 
Evaluation of Medical Products (EMEA), which is responsible for approvals of 
pharmaceutical innovations in the European Union. In Germany, European directives are 
presently in the process of being implemented as part of national law. Here, introduction of 
European law has led to the 12th amendment of the German Drug Code (German acronym 
AMG). However, as implementation of European law would require a more utilitarian view 
on clinical trials and innovation of new drugs (i.e. actions are to be judged on the basis of how 
their outcomes affect the general utility of society, even when some individuals might be 
worse off), medical professionals are rather pessimistic about any practical help from the 
latest amendment because of ethical concerns.   
Thus, economic incentives, legal restrictions and ethical concerns seem to be responsible for 
the lack of innovative activity targeted at drugs for children, though social cost-benefit 
considerations (i.e. welfare analysis) would most probably predict a high gain from the 
introduction of critical innovations. Grounded on the highly interdisciplinary interplay 
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between medical, pharmaceutical, psychopharmaceutical, psychotherapeutic and economic 
research as well as ethical restrictions, this survey aims at analysing channels of influence that 
might be helpful both in the analysis of the innovation process of drugs for children, and in 
improving the uncertain situation of pediatric therapy. We are going to highlight the influence 
of public policy, legal restrictions, enrolment of children in clinical trials, role of parents and 
doctors, as well as possibilities and limits of patent designs. Moreover, as pharmaceutical 
innovations touch on the current discussion on chances and risks of the biotech revolution, 
there is an ongoing feedback from innovative activity to society, and both public discussion 
on and attitudes towards topics such as off-label medication will in turn have a sustainable 
effect on future legal restrictions and, thus, on future innovations. Our survey will be guided 
by this reflexive view of the modernisation and innovation process.  
This paper, written by an economist and two researchers from medical science, intends to give 
an interdisciplinary survey of the problem. We start by presenting some remarks on modern 
innovation processes from the general viewpoint of social sciences. We then inform about the 
innovative process in medical and pharmaceutical sciences under consideration of medical 
science, economic incentives and disincentives, as well as legal and ethical restrictions.  
 
2. Innovations in the Post-Schumpeterian World of Reflexive Modernisation.  
The German Ministry for Education and Research designated the year 2001 the year of “life 
sciences” and sought to support “verantwortbare Innovationspotenziale” (Bundesministerium 
für Bildung und Forschung (o. J.): Aktionsprogramm Lebenswissenschaften).1 The German 
Chancellor Gerhard Schröder has declared 2004 to be the “Jahr der Innovationen”, i.e. the 
year of innovations. 
These examples show that “innovation” has become a common expression, especially in 
political parlance, revealing the urgent need of (German) society to keep pace with recent 
technical, social and economic changes. Although politicians are rather unspecific and fuzzy 
in their terminology, there is a common sense that spurring innovative activity has become 
one of the uppermost goals of modern societies.  
However, the situation has become more complex than it was before, as can be seen from the 
example of the achievements of the pharmaceutical industry in general, and from the limits to 
                                            
1 See http://www.bmbf.de/pub/0330leb.pdf 
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innovative progress set by economic market failure and by ethical concerns in the case of 
therapeutic innovations for children in particular. Whereas innovative activity primarily arose 
in a process well described as “creative destruction” by Schumpeter in his work “Capitalism, 
Socialism and Democracy“ (1943), grounded on the idea that brilliant individuals (risk-taking 
entrepreneurs and inventors) such as Werner von Siemens or Alexander Graham Bell are the 
driving force of technical progress, we nowadays face a “post- Schumpeterian” paradigm 
(Rammert, 1997a), where neither single entrepreneurs nor public R&D institutions 
(universities, Max-Planck-Institutes, etc.) have the capabilities to succeed in a single-handed 
effort. Instead, powerful and heterogeneous networks are needed to solve complex problems 
that simultaneously touch on scientific, social, economic, legal, environmental and ethical 
problems (see Rammert 1997b, 1999). Rammert (1999) presents an example of an innovation 
in medical science (related to Alzheimer disease), where 34 authors from bio-technical firms, 
pharmaceutical multinationals, a top university, a public research institution and a private 
non-profit research lab were involved.  
Thus, unlike the Schumpeterian world which was based on the idea that inventions were 
developed and brought to market in a straightforward and “linear” way, innovations in the 21st 
century often suffer from the risks of ambivalent and unexpected side effects (i.e. negative 
external effects in terms of economics) which touch on the interests of third groups and 
require co-operation in many fields, and acceptance or at least toleration from other key 
players such as government, political parties, trade unions, church, civic action groups, ethics 
commissions etc. Thus, innovations in modern societies and resulting risks need to be 
considered in the way they impact on social innovations (see Areger 1976) and in particular in 
the context of  “reflexive modernisation” (“reflexive Modernisierung”) in the sense of Beck 
(see Beck 1986, Part 3, and Beck et al, 1996). We can conclude, as van de Ven (1988) has put 
it, “innovation [...] is a network effort”, ( p. 115),  and “[...] a collective achievement” (p. 
105).2  This process is better described as one of back-and-forth or even as a zigzag walk 
which eventually leads to a final innovative outcome that might look very different from first 
preliminary ideas.  
The climate described above very well fits the situation of the health sector, the 
pharmaceutical industry and in particular the field of research affecting minors. The health 
sector constitutes a typical sector in need of changes and innovation with paramount 
                                            
2 Quoted in Gillwald (2000).  
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importance for society in terms of long-term and short-term consequences (see, for instance, 
Wichert 2003). On the one hand, innovations in the medical and health sector occur at a rapid 
rate, partly with paradigm changes in quick succession that, in turn, have an effect on further 
research. Here, the advances of the biotech revolution seem to open new horizons of scientific 
research. This system is, on the other hand, particularly susceptible to disturbances that 
hamper or prevent innovation (see also the discussion in Rogler & Schölmerich 2000, Raspe 
2001).3 Overcoming the limits to innovation requires knowledge of the interplay between 
innovation and its acceptance in society, because societal attitudes (in particular with respect 
to ambivalent and unexpected results) will feed back to innovative activities. 
  
3. The Market for Pharmaceuticals, Patents, and Market Failure for Innovations 
Targeted at Children 
There are profound economic reasons that prevent innovations, even when they might be 
highly beneficial from a social cost-benefit point of view. In a manner well-suited to the 
creation of innovations in the field of “trial-and-error” research of pharmaceutics, Schumpeter 
(1911) described innovations4 as “new combinations” (“neue Kombinationen”) that enable 
monopoly rents of pioneering entrepreneurs.  
Classical economic text books on industrial organisation such as that of Tirole (1988)5 
distinguish between product innovation and process innovation. Product innovations create 
new (or considerably improved) goods and services, whereas process innovations reduce the 
cost of producing by introducing new production techniques. Thus, our project on innovations 
in the field of orphan drugs for children deals with product innovations. Although process 
innovations are mostly seen as a matter of higher financial involvement, the picture is 
completely different in the case of pharmaceutical innovations. Darby and Zucker (2003) call 
progress in biotech research a “metamorphic” revolution rather than incremental progress that 
                                            
3 Researchers such as the Vice President of the German Research Foundation (Deutsche 
Forschungsgemeinschaft, DFG), Jörg H. Hacker, point to the crucial importance of key technologies such as 
gene technology for future competitiveness of the German economy and warn against considering only the risks 
of innovations in this field:  „Es stellt sich also die Frage: Ist Deutschland ein Land, das Innovationen auch auf 
dem Gebiet der Gentechnik will, oder werden einseitig die Risiken in den Mittelpunkt der Diskussion gerückt“ 
(Hacker 2004, p.3) 
4 He does so without mentioning the word „innovation“. It appears in his later publication on „Business Cycles“ 
(Schumpeter, 1939). 
5 See, in particular, chapter 10 of Tirole’s book on Research and Development and the Adoption of New 
Technologies.  
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perfects existing products. Innovations are related to huge spending on research and 
development (R&D) which amount to $800 million on average for a single truly new drug 
(see below) and innovations are highly relevant because of their economic relevance as so 
called “drastic” innovations (see Tirole 1988, p. 391 for a formal definition) which allow 
appropriation of the social surplus of monopolistic markets. Due to their enormous 
expenditure on R&D, their potentially huge (but uncertain) profits combined with their 
simultaneous “winner takes it all” risks (leading to patent races), pharmaceutical innovations 
are often referred to as “blockbuster innovations” (see Scherer 2002, among others).  
Incentives to develop new pharmaceutical products and the regulation of the market by patent 
protection can be well understood using Schumpeter’s (1943) classical work. Schumpeter’s 
basic point is that monopoly situations and R&D are intimately related. Monopolies are 
“natural breeding grounds” for R&D, and if one wants to induce firms to undertake costly 
R&D as in the field of pharmaceuticals “... one must accept the creation of monopolies as a 
necessary evil” (Tirole 1988, p. 390). The presence of generics draws attention to the point 
that innovations, when published, attain the status of a public good.6 Thus the creation of new 
pharmaceutical products is encouraged by a system of patents throughout the world. The 
dilemma of the patent system is that, in preventing immediate production of generic products 
which are less expensive to patients, it creates a non-competitive situation which might be 
different from that of a social welfare optimum. As a general rule, however, insights dating 
back to Nelson (1959) and Arrow (1962), according to which even partial imitation of 
discoveries may yield particularly low incentives to do R&D, seem to characterise research 
policy and patent systems in the field of biomedical and pharmaceutical research. 
Pharmaceuticals crucially rely on patent protection, and changes to law and regulation would 
affect incentives to invest substantially. 
On the supply side, the market for pharmaceuticals is highly international, leading to a rather 
low concentration rate. However, recent developments reveal increased merging and 
acquisition activities such as attempts at hostile takeover (see Aventis-Sanofi). A substantial 
share of market profits is achieved from generic producers who compete with R&D-oriented, 
branded firms. Profit margins of branded firms are under pressure because generic products 
                                            
6 A public good is defined as non-rivalrous, i.e. it does not exhibit scarcity, and once it has been produced, 
everyone can benefit from it in a non-excludable way, meaning that it is impossible to prevent people from 
gaining access to the good.  
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are now available only a few months after end of patent, and because generics are 
increasingly favoured by insurance coverage. 7 
Who demands pharmaceuticals? Demand is driven by the needs of patients and the knowledge 
of physicians. As the size of the market determines the amount of sales, economists typically 
emphasise profit (i.e. sales minus costs) incentives and the size of the market as major driving 
forces of innovative activity. Recent results by Kremer (2002) and Acemoglu and Linn (2003) 
on innovations in the pharmaceutical industry confirm classical arguments put forward by 
Schmookler (1966) according to which “the amount of invention is governed by the extent of 
the market”.  
Thus, as children have a much lower probability of being a customer of pharmaceutical 
products, market incentives to produce drugs for children and juveniles are rather small.8 
Exceptions are vaccines (if applicable to all children) and some cough and cold medicines 
(see Meadows, 2003). Meadows (2003) reports US experience where experts see small 
financial benefits as the primary reason why there is a lack of pediatric drug testing.  
The second reason might be even more important in Europe and Germany than in the U.S. It 
has to do with ethical issues that make it more difficult and costly to carry out studies on 
children. As will be described in more detail below, it is necessary to dispose of “child-
friendly environments in any sense, from age-appropriate equipment and medical techniques 
to pediatric specialists who are sensitive to a child’s fear” (quote D. Murphy, director of the 
U.S. Food and Drug Administration’s (FDA) Office of Pediatric Therapeutics, Meadows 
2003). Because highly elaborated ethical procedures have to be administered, the problems 
associated with “informed consent” to participate in a clinical trial would, from a pure 
company-specific cost-benefit point of view, drive up development costs (see below). As, on 
the other hand, market sizes are rather small, opportunity costs of developing new products 
for children are prohibitively high. Expected revenues from orphan drugs and neglected 
studies for children are too small to justify the high fixed and potentially sunk costs of 
pharmaceutical R&D.  
                                            
7 Grabowski (2003a) reports U.S. evidence, according to which for the 1994-79 cohort of brand name products, 
generic drugs captured a 64 percent market share after one year on the market. This increased to 73% after the 
second year.  
8 Moreover, the market of the younger generation is losing ground relative to the market of the older generation. 
Whereas the share of young people under 20 years of age was 30% in 1970 in Germany, it will go down to only 
17.1% in 2030. At the same time, the ratio of the population of more than 60 years of age will increase from 
19.9% in 1970 to 34.4 in 2030 (Statistisches Bundesamt, cited by Frankfurter Allgemeine Sonntagszeitung, April 
17th, 2004, p. 35). 
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4. Cost-Benefit Considerations and the Value of Medical Research   
As has been emphasised above, the unregulated market for drugs for children and for orphan 
drugs in general does not entail the market power necessary to create innovations. To protect 
intellectual property and to spur innovations, governments of most countries regulate the 
market by allowing ownership of monopoly right, i.e. patents, for a duration of 20 years.9  
After 20 years the patent becomes free for use. To understand the social benefit net of costs 
from patents and development, some information on costs and benefits of producing 
pharmaceutical products is appropriate.  
Research and development of pharmaceuticals is a long, risky and very costly business (see 
Grabowski, 2003a, for a recent survey). According to Di Masi et al. (2003), the average 
capitalised R&D cost for a truly new drug10 during the preclinical and clinical R&D phases 
amount to $802 million. Figures published by FDA (FDA 2004) even report costs ranging 
between $0.8 and $1.7 billion. Recent data suggest that the investment required to launch a 
new drug has risen 55 percent during the last five years (FDA 2004)11. One of the main 
reasons R&D is so costly is that most new drug candidates fail to reach the market. Typically, 
less than one percent of the compounds examined in the preclinical period reach the phase of 
human testing, and only 20 percent of the compounds entering clinical trials gain FDA 
approval (Di Masi, 1995).  
Despite such huge costs, patent protection leads to monopoly profits, provided market sizes 
are sufficiently large. Such returns on R&D can be enormous though present values of net 
revenues exceed average R&D costs only for the top three deciles of new drug introductions 
(see Grabowski, Vernon and Di Masi, forthcoming, and Grabowski 2003a). This once again 
confirms the inherent risk of new drug introductions which can be more easily covered by risk 
diversification (development of a portfolio of new drugs) by large multinational companies. 
                                            
9 In Germany, average effective duration of patent protection is 8 years. Patents need to be registered in the very 
early stage of development, testing new drugs takes about 10 years and the process of formal approval by the 
patent office and the Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM takes another two years (BPI 
2003, p.59-60). Recent evidence for the US (Grabowski, 2003) reports that the cohort of new biopharmaceutical 
innovations in 2000-01 had a total clinical development time (i.e. without preclinical studies, but with FDA 
approval) of 86 months. 
10 This refers to submissions on new molecular entities (NMEs). 
11 See also the related article in „Frankfurter Allgemeine Sonntagszeitung“ dated March 27, 2004: „Was neue 
Pillen kosten“. 
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While private (company-specific) cost-benefit considerations of introducing new drugs might 
not have been a success in each single case despite patent protection, the benefits to society of 
new drugs are quite high and far exceed (mostly private) costs. There are at least three recent 
contributions to the literature underlining this result: Lichtenberg (2003b), providing new 
evidence and a survey of his own recent research on this topic (see, in particular, Lichtenberg 
1996, 2003a), Nordhaus (2003) and Murphy and Topel (2003). Benefits arise from longevity 
increase12 , improved quality of life, higher productivity (less working days lost, including 
those of close relatives), and reduced total medical expenditure. Focusing on the benefits of 
longevity as an example, Lichtenberg presents econometric evidence based on data from 
1961-1997 indicating that the average new drug approval increases life expectancy of people 
born in the year in which the drug is approved by 0.016 years (5.8 days). Accumulating direct 
and indirect effects from later cohorts and taking account of the fact that there are 4 million 
births per year in the U.S., the average new drug approval increases the total expected life-
years of current and future cohorts by 1.2 million. Lichtenberg compares these benefits to the 
costs of bringing new products to the market which he estimates to be about $500 million, 
leading to cost per life-year gained to be in the order of $424 ($500 million/ 1.2 million life-
years).  
Opportunity costs of not disposing of new drugs require monetizing the value of better health 
and longer life. William Nordhaus (2003), along with Kevin Murphy and Robert Topel 
offered parallel estimates of the value of recent increases of longevity.13 Murphy and Topel 
(2003) estimate the economic value of a life-year on the order of $150,000, rendering costs of 
$424 per life-year estimated by Lichtenberg (2003b) only a small fraction of social benefits. 
Murphy and Topel (2003) estimate the total value of increased longevity to entire U.S. 
population to be $57 trillion over the period 1975 to 1995.  
Lichtenberg (2003b) reports further efforts to estimate benefits from quality of life and from 
reduced medical expenditures, and he also presents case studies of orphan diseases. Summing 
                                            
12 Note that costs in the final two years of life are lower for people who live longer (Lichtenberg, 2003b, p. 46).  
13 It may scarcely seem possible or even morally offensive to put monetary values on human life. But modern 
econometrics has devised a credible method based on compensating wage differentials for people changing to a 
job with a higher risk of death. This technique is based on the observation that people have to be “bribed” in 
everyday settings to incur small but predictable increases in the risk of death. Extrapolation of both risks and 
compensations obtained for taking higher risks leads to estimated values of statistical lives. Related to this, see 
also the interview with Professor Martin Hellwig (Frankfurter Allgemeine Sonntagszeitung, August 24th, 2004). 
On being asked whether death could be subject to cost-benefit considerations, he answered:  „Das tut jeder, der 
vor einem heranfahrenden Auto über die Straße geht , auch jeder der zur Polizei oder zur Feuerwehr geht, statt in 
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up, social gains from new pharmaceuticals are quite high and exceed costs. High welfare 
benefits seem to suggest that the public sector could do much more to subsidise R&D of 
drugs, in particular orphan drugs and drugs for children. The problem is that welfare gains 
such as those stemming from longevity are intangible gains such that other incentives and 
regulatory solutions need to be found for practical policy purposes. 
 
5. Innovation in Child and Adolescent Psychiatry - Medical-Scientific Approach to 
Pharmacologic R&D for Minors 
Considerations of the last section represent incentives and obstacles of the economic approach 
to research activities for minors. Medical science and the community of physicians, however, 
discuss somewhat deviating desiderations and other intentions for R&D in pediatrics and in 
child and adolescent psychiatry. According to the image medical science has of itself, not 
only financial aspects promote research, and not only research fit for markets has been 
developed (see below). In the international community of researchers into psycho-
pharmacology needs for R&D are clarified, without the economic environment becoming 
substantially changed. During the 1990s, it became more common to use pharmacological 
interventions to treat children with a variety of psychiatric disorders, although incentive 
programs for research and licensing of drugs for minors began later or just at this time (Zito et 
al 1999, Olfson et al. 2002). It seems that it was not only or not primarily economic (more 
precisely, financial) aspects that pushed treatment options and research into drugs for minors.  
As Shirkey and Rylance recognized in the 1960ies and 1970ies, children are therapeutic 
orphans and an underprivileged group in drug-therapy (Shirkey 1968, Rylance 1979). With a 
delay of about one generation a general change of attitude in the scientific community 
towards research on medication for children is now taking place (Thiele, Rheinberger 2003). 
The last few years have seen a major expansion of child-related research on psychotropic 
medications subsequent to increasing use of psychotropic medications in children and recent 
legislative incentives to industry (Riddle et al. 2001, Vitiello et al. 2004). In the rapidly 
changing context of pharmacological research, the interface between publicly and privately 
funded research needs to be reconsidered in order to integrate activities and avoid unnecessary 
                                                                                                                                        
einem Büro zu arbeiten“. Most estimates for the value of a statistical life are within the relatively narrow $ 3 
million to $7 million range. 
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duplication of efforts. Once, by default, the almost exclusive domain of public research, child 
research is now increasingly funded by industry (Vitiello et al. 2004).  
The phenomenon of increasing pharmacological research and treatment has not brought about 
a sufficient availability of registered drugs. In contrast, the increasing off-label use of 
psychotropics in children, coupled with the lack of adequate data to support their efficacy and 
safety, was eventually recognized as an important public health issue to be addressed through 
research in both the U.S. (Vitiello & Jensen, 1997; Jensen et al. 1999) and Europe (Fegert 
2003). In spite of the orphan drug regulations in Europe since 2001 until now (see below), 51 
drugs or application modifications have been licensed. Only two substances for psychiatric 
disorders are among these products, whereas the majority of drugs concern treatments for 
allergic diseases, vaccinations and application modifications (VFA 19.2.2004).14 By contrast, 
in the list of FDA indicating the further research required for minors, 21 substances for 
neurological or psychiatric disorders are itemized (FDA v. 2002). 
 
6. Legal and Ethical Restrictions for Scientific Medical Research  
6.1. International Experiences of Legal Regulations on R&D of Pharmaceuticals for 
Children   
The innovation of drugs is protected by patent law. Without such governmental regulations 
market failure would have prevented expensive and risky R&D on pharmaceuticals. While 
market size seems to be sufficiently large in particular for drugs of the elder generation, 
market failure seems to be still dominant for orphan diseases and third world diseases like 
malaria.  
The U.S. 1983 Orphan Drug Act (ODA) provides an interesting experience worth being 
considered and extended as a solution to European and German problems. ODA covers drugs 
which treat diseases affecting a small number of people (less than 200,000 in the US, which is 
equivalent to about 7.5 patients / 10,000 inhabitants).15 The Act is based on the economic 
                                            
14 In detail, in 2001 14 substances/application modifications (s/am) were licensed, in 2002 22 s/am, in 2003 13 
s/am, in 2004 2 s/am. VFA: Europäische Zulassungen und Zulassungserweiterungen für Arzneimittel oder 
Applikationshilfen, 19.2.2004 
15 See, among others, Rohde (2000), Kleist (2001), Stürchler (2002), Meadows (2003), Grabowski (2003b). See 
also file: http://www.orphan-europe.com/orphan_druglegislations.html 
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incentives described above.16 Of the three primary incentives incorporated in the Act, the 
seven-year grant of market exclusivity17 is considered the most significant by the drug 
industry (see corresponding statements in, for instance, Rohde, 2000, or Meadows, 2003). 
Indeed, the annual average number of drugs for rare diseases brought to market during 1983-
1999 was twelve times as great as it was during 1973-1982 (Lichtenberg 2003b, p.47).  
To avoid the problem of off-label use and to spur R&D of drugs for pediatric use, even 
greater and particular efforts were needed. The FDA tried to follow a carrot-and-stick policy. 
While the “carrot” is given by the market exclusivity described above, the “stick” was 
represented by the so called “pediatric rule”. The FDA tried to require pediatric studies of a 
new drug submitted for approval if the product was likely to be used for pediatric patients. 
The idea was to avoid off-label use, that is, children should have access to drugs properly 
tested for pediatric use. However, the pediatric rule, added to the existing legislation of ODA 
in 1997, failed to be relevant in reality. It was criticised because of the missing legal authority 
of the FDA to require pediatric rules and finally overturned by the federal court in 2002 
(Meadows 2003).  
In June 1998, existing legislation of ODA was refined when the U.S. Congress passed the 
Food and Drug Administration Modernization Act which provided financial incentive to the 
pharmaceutical industry in return for conducting pediatric research, and legislation was then 
further expanded and extended until 2007, with the Best Pharmaceuticals for Children Act 
(U.S. Congress 2002). The additional incentive (i.e., a 6-month extension in the drug patent 
exclusivity) has substantially changed the approach of industry to pediatric pharmacology, 
also including pediatric psychopharmacology. As of January 31, 2004, pediatric studies had 
been requested by the Food and Drug Administration (FDA) for a total of 283 drugs, of which 
36 (13%) were neuropharmacological medications (FDA 2003a). As of February 25, 2004, 
the 6-month additional exclusivity for pediatric studies had been granted by FDA for 94 
drugs, 10 (11%) of which were neuropharmacological medications (FDA 2003b). Although 
many of these studies are rather small pharmacokinetic and dose-ranging investigations, 
insufficient per se to support pediatric indications, their number attests to the new vitality of 
                                            
16 It is based on three primary incentives: 1) 50% tax credit for R&D expenses incurred in clinical trials, 2) 
federal funding of grants and contracts for clinical trials of orphan products, and 3) grant of an exclusive right to 
market the orphan drug for seven years from the date of FDA approval 
17 Note that “market exclusivity” goes beyond (and probably extends) patent protection. The main advantage is 
that monopoly rights can be protected against imitators and competitors in a more effective way than with 
patents (see Stürchler, 2002).  
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the field. The recently passed Pediatric Research Equity Act of 2003 (U.S. Congress 2003), 
which provides FDA with the authority to request industry to conduct pediatric studies even 
before drugs are approved for marketing, is likely to further spur child research. 
Other countries followed the US example. Japan introduced the Orphan Drug Legislation in 
1993, Australia started its Orphan Drug Program in 1998. The European Union followed the 
U.S. example by launching the European Agency for the Evaluation of Medical Products 
(EMEA), which is responsible for approvals in the European Union.18  
At present, European directives are in the process of being implemented as part of national 
law. In this context international guidelines on Good Clinical Practice (GCP) are going to be 
valid for the USA, Japan and Europe. The GCP guideline is currently being implemented via 
EU directive 2001/20 into European national law. GCP is considered as the central guideline 
applicable to research projects as “an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting trials that involve human subjects. 
Compliance with GCP assures that the rights, safety, and well-being of trial subjects are 
protected and that the clinical trial data are credible.”19 (Federal Register Vol.62, No.90, May 
9, 1997, pp. 25691-25709)  
In Germany, implementation of European law has led to the 12th Amendment of the German 
Drug Code (German acronym AMG), and is the subject of discussion as draft legislation in 
the corresponding committees.20 Experts see the effects of the implementation of the GCP 
guideline in a rather critical light: higher regulatory requirements might cause a decline in the 
number of clinical studies, and industry-funded research may hardly be performed in future.21  
Thus, national programs similar to those launched by the US government have not yet been 
implemented in Europe. It is an open question whether European or German law would lead 
to a decision similar to patent exclusivity. 
                                            
18 In the EU, orphan diseases are defined by applying a prevalence rate of 5/10,000. EMEA has extended market 
exclusivity for the duration of 10 years, but it can reduce this period to a limited duration of 6 years if profits are 
sufficiently high. 
19 About the international validity of GCP: “This International Conference on Harmonization (ICH) guidance 
provides a unified standard for the European Union, Japan, and the United States to facilitate the mutual 
acceptance of clinical data by the regulatory authorities in those jurisdictions.” 
20 The planned date for implementation (May 2004) will not be met, not only in Germany. 
21 This topic was discussed at an international conference in Munich 2004: EU Clinical Trial Directive, 
Regulators´ Interpretation and Implementation Advice, 26th Feb 2004. The lecture of B. Hart, Director of 
Clinical Science, AstraZeneca, UK, especially, mentioned the loss of competitiveness of Western Europe as 
Trial Center.  
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6.2. Ethical Concerns  
Moreover, there are strong rules for protection scope aimed in particular at groups and 
persons who are not able to give consent (Buchanan, Brock 1989, McCormick 1989, Levine 
1986, p. 236, Arras & Rhoden 1989). Remembering the inhumane experiments of National 
Socialist researchers in concentration camps, especially dependent persons such as minors, 
mentally disabled and psychiatric patients are understood as such people or groups (Dahl, 
Wiesemann 2001; Bücheler et al. 2002; Thiele, Rheinberger 2003; Weiss Roberts & Roberts 
1999; Vollmann 2000). However, in legal regulations applicable to date the inability of 
minors to give consent was generally assumed and was neither questioned nor the subject of 
scientific research (Graham 1991, p. 355, Rothärmel et al. 1999, Robinson 2001, Fundudis 
2003, Kölch 2003).  
In Germany, due to various reasons, a rather restrictive legislation is to be assumed, 
characterized by the idea of putting the protection of the individual human being before the 
collective interests. There is a climate of utmost reluctance in Germany towards medical trials 
on persons who are not able to give their consent and also a rather reluctant attitude towards 
relaxation of strict regulations that aim primarily at the protection of the individual. 
The 12th Amendment of the German Drug Code (“12. Novelle zum Arzneimittelgesetz”, May 
2004), has brought new elements to the debate. The importance of general (aggregate) utility 
(“Gruppennutzen”) has for the first time been acknowledged and mentioned in an explicit 
way. In accordance with Bentham’s (1748 – 1832) utilitarianism, actions are to be judged 
strictly on the basis of how their outcomes affect the general utility (aggregate utility) of 
society, implying a stronger focus on the utilitarian view of clinical trials and development of 
new drugs. Thus, economic cost-benefit considerations which most probably would predict a 
high social surplus from R&D of drugs for minors would have to be seen in a different light. 
However, as such social gains are mostly intangible - unless insurance companies are 
involved - and because individual human rights have utmost priority, it is unclear what 
pointing to aggregate utility will mean in legal and medical practice.  
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7. Organisation of Research Networks: Institutional Aspects  
Medical research today is performed in academic research at universities and public/national 
research institutes, in research institutions financed by the pharmaceutical industry and by 
foundations. There is interaction among these sectors: Industry supports pediatric 
psychopharmacology research through investigator-initiated grants and by giving unrestricted 
grants to academic sites. Unrestricted grants are an extremely valuable source of funding for 
academic child research as they are typically utilized to fund add-on projects to existing 
studies, train junior investigators, or conduct innovative pilot studies, often in less prevalent 
disorders, such as autism or Tourette’s disorder (Sallee et al. 2000). 
R&D of new drugs is the domain of industry-sponsored research. However, there are 
fundamental differences between the US and Europe: In the U.S., a substantial share of 
research is governmentally funded, and, as is the case with the NIMH, researchers possess a 
powerful research institution which is urged to investigate psychiatric diseases and which has 
its own department dealing with child and adolescence-related issues (NIMH Child and 
Adolescent Treatment and Preventive Intervention Research Branch). Furthermore, in the 
USA public funding for research in pediatric psychopharmacology has grown substantially.22 
There is no equivalent European institution with similar influence and research budget 
(Vitiello et al. 2004). In particular, NIMH supports research projects which are of no interest 
for industry because of lacking market sizes, but which are needed for minors, for instance by 
projects on the relative efficacy of pharmacotherapy combined with psychosocial 
interventions, or with combined use of pharmacotherapy and psychosocial interventions.23 As 
a result, testing clinically important questions with adequate statistical power and thus 
arriving at definitive conclusions about the treatment efficacy is possible.  
The public funding of research in minors has great importance because industry-sponsored 
research has limitations. Vitiello et al. emphasize the problematic lack of freedom of 
information (Vitiello et al. 2004): the exclusive property rights of sponsors to databases of 
industry-sponsored studies often make it difficult or impossible for academic researchers to 
have direct access to the entire research data collected in multi-site clinical trials. In general, 
these databases cannot be accessed through the U.S. Freedom of Information Act. There are 
                                            
22 By NIMH the extramural intervention research funding in children from 1997 to 2003 for pediatric 
psychopharmacology increases more than three times about to $39 million. (Vitiello et al. 2004) 
23 These trials are often conducted under cooperative agreements or contracts, which are collaborative efforts 
between academic investigators and NIMH researchers (Lebowitz et al 2003) 
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no guarantees that research findings will be published if they are not of interest to industry.24 
Recent difficulties in addressing concerns about a possible link between SSRI antidepressant 
use and suicidal behavior in youths can be in part ascribed to the lack of standardized and 
sensitive methods for safety ascertainment (FDA 2004, Fegert 2004). 
Industry-funded studies are less likely to be published than other studies (Lexchin et al. 2003) 
and are more likely to report conclusions favorable to their product (Melander et al. 2003; 
Als-Nielsen et al 2003). This bias adds to the fact that journals have been reluctant to publish 
data from studies that fail to detect treatment effects. On completion of a multi-site trial, 
investigators are typically given a copy of the data collected at their site, but not the entire 
study database (Pharmaceutical Research and Manufacturers of America 2002). Secondary 
data analyses cannot be conducted independently by the investigators.  
Vitiello et al. carried out domains for research where non-industry-initiated studies are 
requested (Vitiello et al. 2004): these are questions without the promise of profit, but are of 
high interest for physicians and minors. Examples are given by research into the efficacy and 
safety of combined treatments, either psycho-pharmacon in combination with psychotherapy 
or psycho-social interventions or the combination of two or more medications for the 
purposes of augmenting therapeutic effects. Trials on efficacy and safety of interventions for 
treatment-resistant children and the long-term effects of medication are necessary, as are trials 
on the impact of treatment on distal outcomes, prognosis of illness and level of functioning; 
treatment development and testing in less common conditions for orphan drugs; search for 
moderators of treatment response, which can lead to the identification of patient subtypes 
most sensitive to the effects (positive and negative) of medications; studying the effect of 
medications on development; etc.  
 
8. Conclusions 
Lack of economic incentives, legal restrictions and ethical concerns seem to be responsible 
for the absence of innovative activity targeted at drugs for children, though social cost-benefit 
considerations (i.e. welfare analysis) would most probably predict a high gain from the 
introduction of critical innovations. This interdisciplinary survey informs about the highly 
                                            
24 For drugs for which the FDA approves an indication, the data and information provided to the FDA advisory 
committee can be released to the public. However, data from studies that do not lead to marketing approval of an 
indication or other label changes cannot be accessed without industry permission. (Vitiello et al. 2004) 
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complicated innovation process, which, on the one hand touches on the current discussion on 
chances and risks of the biotech revolution, and which is affected by the public discussion and 
attitude on topics such as off-label medication and clinical tests on children on the other hand. 
The focus is on the evaluation of specific pathways towards successful (or less successful) 
innovative outcomes. Among others, the influence of public policy, legal restrictions, 
enrolment of children in clinical trials, role of parents and doctors, as well as possibilities and 
limits of patent designs are discussed. Cooperation of academic research at universities and 
public/national research institutes, and research institutions financed by the pharmaceutical 
industry and by foundations is seen as an important source of future progress.  
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